For the Patient

We are developing human acid ceramidase to treat devastating disease caused when a patient’s own cells do not produce enough acid ceramidase.

Acid ceramidase is an enyzme which breaks down ceramide. Ceramide is an essential lipid or fat, which in excess, causes cell death.


References

 

News

  • Plexcera Tackling Rare, Oft-Misdiagnosed Farber Disease
    September 16, 2013

    September 16, 2013 – Pitching a rare disease program to prospective partners and investors these days sounds like it should be a fairly easy task. Biotech and pharma firms have more than 500 programs in the rare disease pipeline and orphan indications are an increasingly hot property for the industry. (See BioWorld Insight, April 29, 2013.) But “working on a disease that’s unfamiliar to physicians […]

  • Mount Sinai Grants Exclusive License to Plexcera Therapeutics to Develop Treatments for Farber Disease and Cystic Fibrosis
    September 10, 2013

    September 10, 2013 – Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, has granted an exclusive license to Plexcera Therapeutics, LLC  to commercially develop recombinant human acid ceramidase (rhAC) to treat diseases caused by genetic or disease-induced deficiencies in the enzyme rhAC. Mount Sinai is promoting the scientific discoveries of […]